A Window Study of Ixazomib in Untreated Indolent B-NHL.
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Ixazomib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 05 Feb 2018 Planned primary completion date changed from 1 Dec 2021 to 30 Dec 2021.
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2016 Status changed from not yet recruiting to recruiting.